To compare the safety and efficacy of terbinafine with placebo, itraconazole and griseofulvin.
itraconazole and terbinafine versus griseofulvin were presented. A potential reason for the significant heterogeneity of terbinafine versus itraconazole was considered in the text.
Results of the review
Nine RCTs (2,227 patients) were included in the review.
Terbinafine versus placebo (3 RCTs, 588 patients): compared with placebo, terbinafine significantly improved the cure rates at 12 weeks; the RR was 9.07 (95% CI: 5.14, 16.02).
Terbinafine versus itraconazole (4 RCTs, 1,264 patients): compared with itraconazole, terbinafine significantly improved the cure rates at the end of treatment (12 to 16 weeks); the RR was 1.64 (95% CI: 1.48, 1.81). The forest plot showed significant heterogeneity with one RCT showing greater efficacy than the other 3 RCTs. The authors suggest this may be due to the one RCT using a higher dose of itraconazole (400 mg) for one in every 4 weeks. Terbinafine was reported as being better tolerated by patients and physicians than itraconazole (RR 1.22, 95% CI: 1.14, 1.31). However, it was unclear how the reported RR for this outcome was assessed. There was no significant difference between the treatments in terms of the adverse event rates; further details were not presented.
Terbinafine versus griseofulvin (2 RCTs, 375 patients): compared with griseofulvin, terbinafine significantly improved the cure rates at 24 weeks; the RR was 1.31 (95% CI: 1.10, 1.56).
